CYSTIC FIBROSIS GENE MUTATIONS

• US 20100317017A1
• Filed: 07/28/2010
• Published: 12/16/2010
• Est. Priority Date: 03/05/2004
• Status: Active Grant

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: BULLER, ARLENE M., PENG, MEI, MCGINNISS, MATTHEW J., SUN, WEIMIN, QUAN, FRANKLIN
• Granted Patent: US 8,076,078 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.

Claims

1. A method of determining the cystic fibrosis status of a human comprising:

(a) determining the presence or absence of the 3429C->

A mutation in both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene in a nucleic acid sample obtained from the human, and

(b) identifying the human

(i) as having cystic fibrosis or being predisposed to cystic fibrosis when the human is homozygous for the 3429C->

A mutation in the CFTR gene, or

(ii) as being a cystic fibrosis carrier when the human is heterozygous for the 3429C->

A mutation in the CFTR gene, or

(iii) as having no predisposition or carrier status caused by the 14840->

T mutation when the 3429C->

A mutation is absent from both alleles of the CFTR gene.

4. The method of any one of claims 1-3 wherein genomic DNA is tested for the presence of said mutation.

5. The method of any one of claims 1-3 wherein a cDNA copy of the CFTR coding sequence is tested for the presence of said mutation.

6. The method of any one of claims 1-3 wherein the presence of said mutation is determined by nucleic acid sequencing.

7. The method of any one of claims 1-3 wherein the presence of said mutation is determined by restriction fragment length polymorphism analysis following treatment of CFTR gene sequence with at least one endonuclease restriction enzyme.

8. The method of any one of claims 1-3 wherein the presence of said mutation is determined by allele specific amplification.

9. The method of any one of claims 1-3 wherein the presence of said mutation is determined by primer extension.

10. The method of any one of claims 1-3 wherein the presence of said mutation is determined by oligonucleotide ligation.

11. The method of any one of claims 1-3 wherein the presence of said mutation is determined by hybridization with a detectably labeled probe.

2. A method of determining if a human is predisposed to cystic fibrosis comprising determining if nucleic acid from the human is homozygous for the 3429C->

A mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene and identifying said human as predisposed to cystic fibrosis when the human is homozygous.

3. A method of identifying a human as having an increased likelihood of having an offspring afflicted with cystic fibrosis, comprising determining if nucleic acid from the human has the 3429C->

A mutation in one or both alleles of the CFTR gene and identifying said human as having an increased likelihood of having an offspring afflicted with cystic fibrosis when said 3429C->

A mutation is present in at least one allele.